A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
Status:
NOT_YET_RECRUITING
Trial end date:
2028-04-15
Target enrollment:
Participant gender:
Summary
This is a long-term, open-label extension study of bivamelagon in participants with Hypothalamic Obesity (HO) who have transitioned from the index study, LG-MCCL005. The study will last up to 2 years.